Profile data is unavailable for this security.
About the company
Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.
- Revenue in AUD (TTM)5.43m
- Net income in AUD-13.67m
- Incorporated1998
- Employees107.00
- LocationSyntara Ltd20 Rodborough RdFRENCHS FOREST 2086AustraliaAUS
- Phone+61 29454-7200
- Fax+61 29451-3622
- Websitehttps://www.pharmaxis.com.au/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Little Green Pharma Ltd | 25.63m | -8.15m | 39.37m | -- | -- | 0.505 | -- | 1.54 | -0.0272 | -0.0272 | 0.0856 | 0.2574 | 0.2772 | 1.05 | 12.29 | -- | -8.82 | -- | -9.74 | -- | 53.18 | -- | -31.81 | -- | 1.39 | -18.90 | 0.0624 | -- | 29.07 | -- | 4.72 | -- | -- | -- |
| Next Science Ltd | 35.79m | -20.73m | 39.44m | -- | -- | 3.63 | -- | 1.10 | -0.0772 | -0.0772 | 0.1313 | 0.0372 | 1.97 | 5.34 | 8.04 | -- | -113.88 | -74.40 | -168.92 | -90.31 | 78.83 | 76.98 | -57.93 | -128.26 | 1.96 | -- | 0.1045 | -- | 89.36 | 50.80 | -28.29 | -- | -2.28 | -- |
| Medical Developments International Ltd | 33.15m | -40.99m | 47.32m | 68.00 | -- | 0.8137 | -- | 1.43 | -0.4627 | -0.4627 | 0.3741 | 0.5162 | 0.4131 | 1.02 | 4.14 | -- | -51.09 | -15.81 | -60.56 | -17.79 | 73.50 | 70.98 | -123.66 | -52.49 | 1.82 | -- | 0.0476 | -- | 2.51 | 9.22 | -630.83 | -- | -20.32 | -- |
| Starpharma Holdings Ltd | 9.76m | -8.17m | 48.08m | 50.00 | -- | 1.69 | -- | 4.93 | -0.0198 | -0.0198 | 0.0237 | 0.0682 | 0.2195 | 0.244 | 1.20 | -- | -18.37 | -27.20 | -24.10 | -33.05 | 93.52 | 77.48 | -83.69 | -269.74 | 4.58 | -- | 0.1115 | -- | 131.84 | 29.10 | 47.79 | -- | -22.29 | -- |
| Inoviq Ltd | 791.70k | -6.55m | 48.51m | 85.00 | -- | 2.30 | -- | 61.28 | -0.0709 | -0.0709 | 0.0086 | 0.1894 | 0.0366 | 4.54 | 0.6418 | -- | -30.33 | -44.62 | -32.64 | -47.55 | 89.77 | -- | -827.88 | -1,928.52 | 7.06 | -- | 0.0198 | -- | 5.29 | 146.33 | 26.92 | -- | -- | -- |
| Radiopharm Theranostics Ltd | 299.23k | -47.95m | 54.32m | -- | -- | 0.4093 | -- | 181.55 | -0.1261 | -0.1261 | 0.0008 | 0.0611 | 0.0041 | -- | 0.1097 | -- | -65.24 | -- | -82.85 | -- | -- | -- | -16,024.17 | -- | -- | -3.91 | 0.00 | -- | 2.35 | -- | -38.54 | -- | -- | -- |
| Vitura Health Ltd | 123.87m | 3.51m | 57.00m | 119.00 | 15.88 | 1.46 | 11.66 | 0.4602 | 0.0062 | 0.0062 | 0.2165 | 0.0674 | 2.10 | 15.04 | 10.74 | 1,040,932.00 | 5.50 | 13.50 | 7.70 | 18.51 | 27.63 | 32.41 | 2.62 | 6.19 | 1.11 | 30.48 | 0.2228 | -- | 5.56 | -- | -74.57 | -- | 155.80 | -- |
| Syntara Ltd | 5.43m | -13.67m | 63.16m | 107.00 | -- | 11.74 | -- | 11.64 | -0.0157 | -0.016 | 0.0057 | 0.0039 | 0.3155 | -- | 0.7918 | -- | -79.44 | -30.68 | -130.63 | -40.26 | -- | -- | -251.77 | -74.66 | -- | -484.90 | 0.0474 | -- | -7.92 | -15.43 | -1.77 | -- | -62.79 | -- |
| Neurizon Therapeutics Ltd | 866.18k | -8.90m | 93.42m | 52.00 | -- | 8.27 | -- | 107.86 | -0.0234 | -0.0199 | 0.0023 | 0.023 | 0.1004 | -- | 10.39 | -- | -103.16 | -31.15 | -118.57 | -35.11 | -- | -- | -1,027.49 | -120.92 | -- | -- | 0.00 | -- | -- | -- | -466.09 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Platinum Investment Management Ltd.as of 18 Oct 2024 | 204.35m | 14.88% |
